Analyst consensus rating
LB Pharmaceuticals Analyst Rating: Strong Buy
LBRX is rated Strong Buy by 8 analysts with a $53.38 target. As of 2026-08-29.
Direct answer
LB Pharmaceuticals's consensus rating is Strong Buy.
8 analysts are included in the current consensus when a coverage count is available.
The same consensus reports an average price target of $53.38.
Forecast evidence checked August 29, 2026.
Get free LB Pharmaceuticals email updates.
Bullstory sends one daily email when new analysis or important company news is available.
Verified data
- Current price
- $47.73
- Average price target
- $53.38
- High price target
- $78.00
- Low price target
- $37.00
- Low target gap
- -22.5%
- Target upside
- +11.8%
- High target gap
- +63.4%
- Target range width
- 85.9%
- Consensus rating
- Strong Buy
- Analysts
- 8
- Evidence date
- August 29, 2026
- Valid through
- September 5, 2026
Explore related company data
Read the frequently asked questions.
What is the analyst consensus rating for LB Pharmaceuticals?
LB Pharmaceuticals has a verified Strong Buy consensus. The same dataset has an average price target of $53.38.
How far are LB Pharmaceuticals's low and high targets from the recorded price?
The low target implies -22.5%, while the high target implies +63.4%.
How many analysts are included in LB Pharmaceuticals's consensus?
The verified consensus includes 8 analysts.
How is LB Pharmaceuticals's target upside or downside calculated?
The average target of $53.38 is divided by the recorded price of $47.73, then one is subtracted to produce +11.8%. This does not guarantee a future return.
When was LB Pharmaceuticals's analyst forecast verified?
The data was verified on 2026-08-29. The dataset is valid through 2026-09-05.